JP2018509423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509423A5 JP2018509423A5 JP2017548144A JP2017548144A JP2018509423A5 JP 2018509423 A5 JP2018509423 A5 JP 2018509423A5 JP 2017548144 A JP2017548144 A JP 2017548144A JP 2017548144 A JP2017548144 A JP 2017548144A JP 2018509423 A5 JP2018509423 A5 JP 2018509423A5
- Authority
- JP
- Japan
- Prior art keywords
- immune complex
- subject
- immunoconjugate
- bladder
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562132246P | 2015-03-12 | 2015-03-12 | |
| US62/132,246 | 2015-03-12 | ||
| US201562267385P | 2015-12-15 | 2015-12-15 | |
| US62/267,385 | 2015-12-15 | ||
| PCT/US2016/022077 WO2016145349A1 (en) | 2015-03-12 | 2016-03-11 | Methods of treatment for epcam positive bladder cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509423A JP2018509423A (ja) | 2018-04-05 |
| JP2018509423A5 true JP2018509423A5 (enExample) | 2019-04-18 |
| JP6824183B2 JP6824183B2 (ja) | 2021-02-03 |
Family
ID=56879840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548144A Expired - Fee Related JP6824183B2 (ja) | 2015-03-12 | 2016-03-11 | Ｅｐｃａｍ陽性膀胱癌の処置方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10576163B2 (enExample) |
| EP (1) | EP3268040A4 (enExample) |
| JP (1) | JP6824183B2 (enExample) |
| CN (1) | CN108513547A (enExample) |
| AU (1) | AU2016228755B2 (enExample) |
| CA (1) | CA2979394A1 (enExample) |
| HK (1) | HK1249020A1 (enExample) |
| WO (1) | WO2016145349A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016145349A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Methods of treatment for epcam positive bladder cancer |
| CA2979400A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Dosing strategies for targeting epcam positive bladder cancer |
| WO2016179001A1 (en) * | 2015-05-01 | 2016-11-10 | Baylor College Of Medicine | Methods for enhancing an immune response with a ctla-4 antagonist |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| CN110804643B (zh) * | 2019-10-29 | 2022-06-21 | 同济大学 | 一种体外评价卡介苗对中性粒细胞活性影响的方法 |
| WO2023141236A2 (en) * | 2022-01-19 | 2023-07-27 | Istari Oncology, Inc. | Methods for treating bladder cancers by intravesical instillation of a chimeric poliovirus |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5082767A (en) | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
| IL98528A0 (en) | 1990-06-21 | 1992-07-15 | Merck & Co Inc | Pharmaceutical compositions containing hybrid for killing bladder cancer cells |
| US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
| GB9709421D0 (en) | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
| US6680296B1 (en) | 1997-06-06 | 2004-01-20 | Tanox Pharma B.V. | Type-1 ribosome-inactivating protein |
| ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
| US6280742B1 (en) | 1998-06-17 | 2001-08-28 | Zonagen, Inc. | Methods and materials for the treatment of prostatic carcinoma |
| ES2308981T3 (es) | 1999-04-09 | 2008-12-16 | Universitat Zurich | Metodo para la estabilizacion de las inmunoglobulinas hibridas o fragmentos de inmunoglobulina y fragmentos anti-egp-2-scfv estabilizado. |
| GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| BR0209177A (pt) | 2001-05-03 | 2004-10-05 | Merck Patent Gmbh | Anticorpo especìfico a tumor recombinante e uso do mesmo |
| US20030148950A1 (en) | 2001-10-09 | 2003-08-07 | Li Xin | Kringle domain 1 of human hepatocyte growth factor and uses therefor |
| CN1604966A (zh) | 2001-10-15 | 2005-04-06 | 免疫医疗公司 | 直接靶定的结合蛋白 |
| US20040022726A1 (en) | 2002-06-03 | 2004-02-05 | Goldenberg David M. | Methods and compositions for intravesical therapy of bladder cancer |
| SI21272A (sl) | 2002-07-31 | 2004-02-29 | LEK farmacevtska dru�ba d.d. | Sintetski gen za humani granulocitne kolonije stimulirajoči dejavnik za ekspresijo v E. coli |
| CA2424255A1 (en) | 2003-03-26 | 2004-09-26 | Claudio Di Paolo | Immunotoxins |
| PT2829283T (pt) | 2003-04-30 | 2017-09-08 | Univ Zuerich | Método para tratamento do cancro utilizando uma imunotoxina |
| CA2560278C (en) | 2004-03-19 | 2012-11-20 | Matthew Baker | Modified bouganin proteins, cytotoxins and methods and uses thereof |
| PL1766017T3 (pl) | 2004-06-10 | 2015-08-31 | Viventia Bio Inc | Przeciwciało specyficzne wobec nowotworu |
| US20090171317A1 (en) * | 2006-03-10 | 2009-07-02 | Ebrahim Versi | Self-Catheterization Device To Administes Compounds To The Bladder |
| WO2008052322A1 (en) * | 2006-10-30 | 2008-05-08 | Viventia Biotech Inc. | Immunotoxγn fusions comprising an antibody fragment and a plant toxin linked by protease cleavable linkers |
| WO2008128330A1 (en) | 2007-04-19 | 2008-10-30 | Viventia Biotech Inc. | Optimized nucleotide sequences of vb6-845 for expression of recombinant proteins |
| CA2700815A1 (en) | 2007-09-27 | 2009-04-02 | Viventia Biotech Inc. | Optimized nucleic acid sequences for the expression of vb4-845 |
| CA2618163A1 (en) | 2008-02-07 | 2009-08-07 | K. W. Michael Siu | Head and neck cancer biomarkers |
| MX2011010469A (es) | 2009-04-08 | 2012-03-14 | Deutsches Krebsforsch | Radicales de enlace al objetivo, armados con amatoxina para el tratamiento del cancer. |
| GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| WO2011116387A1 (en) | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
| WO2012178173A1 (en) | 2011-06-24 | 2012-12-27 | Centrose, Llc | Extracellular targeted drug conjugates |
| CA2909153A1 (en) * | 2013-04-12 | 2014-10-16 | Viventia Bio Inc. | Compositions and methods for detection and treatment of hepatocellular carcinoma |
| CA2915397A1 (en) * | 2013-06-17 | 2014-12-24 | Viralytics Limited | Methods for the treatment of bladder cancer |
| PL3052525T3 (pl) | 2013-10-02 | 2020-03-31 | Viventia Bio Inc. | Przeciwciała anty- EpCAM i sposoby wykorzystania |
| CA2979400A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Dosing strategies for targeting epcam positive bladder cancer |
| WO2016145349A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Methods of treatment for epcam positive bladder cancer |
| WO2017040801A2 (en) | 2015-09-02 | 2017-03-09 | Viventia Bio Inc. | Methods for making and using an immunoconjugate for the treatment of cancer |
-
2016
- 2016-03-11 WO PCT/US2016/022077 patent/WO2016145349A1/en not_active Ceased
- 2016-03-11 JP JP2017548144A patent/JP6824183B2/ja not_active Expired - Fee Related
- 2016-03-11 EP EP16762627.4A patent/EP3268040A4/en not_active Withdrawn
- 2016-03-11 US US15/557,371 patent/US10576163B2/en active Active
- 2016-03-11 AU AU2016228755A patent/AU2016228755B2/en not_active Ceased
- 2016-03-11 CN CN201680027431.4A patent/CN108513547A/zh active Pending
- 2016-03-11 CA CA2979394A patent/CA2979394A1/en active Pending
- 2016-03-11 HK HK18108683.5A patent/HK1249020A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017506217A5 (enExample) | ||
| JP2019511222A5 (enExample) | ||
| JP2019527706A5 (enExample) | ||
| JP2016502515A5 (enExample) | ||
| RU2019106663A (ru) | Комбинированная терапия рака | |
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| JP2018502120A5 (enExample) | ||
| JP2016505635A5 (enExample) | ||
| JP2018535204A5 (enExample) | ||
| JP2019510001A5 (enExample) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| JP2016535009A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2014509841A5 (enExample) | ||
| JP2016529255A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| JP2014158469A5 (enExample) | ||
| JP2016528247A5 (enExample) | ||
| JP2019504105A5 (enExample) | ||
| JP2016539946A5 (enExample) | ||
| JP2017523184A5 (enExample) | ||
| JP2019531293A5 (enExample) | ||
| JP2015505843A5 (enExample) | ||
| JP2017501977A5 (enExample) |